Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.72 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.72 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.72 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.72 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.69 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.68 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.68 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566229 | 1.00 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL3498224 | 1.00 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14199627 | 1.00 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14178408 | 1.00 | SLC28A1 (0.72) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL912472 | 0.90 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL24211446 | 0.90 | SLC28A1 (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2635506 | 0.90 | SLC28A1 (0.69) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL18660222 | 0.89 | P2RY6 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL17577501 | 0.89 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL12701345 | 0.89 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1927 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122060818-A | Chemically modified circular RNA molecules, methods of making and uses thereof | 上海元码智药生物技术有限公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4630049-A1 | IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA AND RSV | Pfizer Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| CN-120092014-A | RNA constructs and uses thereof | 生物技术欧洲股份公司 | 2025-06-03 | — | — | CN | claimed |
| CN-120064427-A | Method and analysis system for detecting brain nucleic acid hydrolysate spatial distribution based on mass spectrum imaging | 北京脑科学与类脑研究所 | 2025-05-30 | — | — | CN | claimed |
| EP-4558218-A2 | GENOME INSERTIONS IN CELLS | Addition Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| EP-4549577-A1 | NOVEL INDUCED CYTOPLASMIC IVT (ICIVT)-LIKE COMPOSITION AND THE RELATED VACCINE MEDICINE DESIGNS THEREOF | Mello Biotech Taiwan Co., Ltd. (TW) | 2025-05-07 | — | — | EP | claimed |
| US-20250115932-A1 | INDUCED CYTOPLASMIC IVT (ICIVT)-LIKE COMPOSITION AND THE RELATED VACCINE MEDICINE DESIGNS THEREOF | MELLO BIOTECH TAIWAN CO., LTD. (TW) | 2025-04-10 | — | — | US | claimed |
| CN-119372129-B | 5-Methyluridine producing strain, construction method and application thereof | 天津科技大学 | 2025-03-18 | — | — | CN | claimed |
| EP-4506456-A1 | NOVEL OXO-RNA COMPOSITIONS AND THE RELATED APPLICATIONS THEREOF | Lin, Shi-Lung (US) | 2025-02-12 | — | — | EP | claimed |
| CN-119372129-A | 5-Methyluridine producing strain, construction method and application thereof | 天津科技大学 | 2025-01-28 | — | — | CN | claimed |
| WO-2011005799-A2 | SELF REPLICATING RNA MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2011-01-13 | — | — | WO | claimed |
| WO-2010111494-A1 | SINGLE MOLECULE SENSITIVE PROBES FOR DETECTING RNA | GEORGIA TECH RESEARCH CORPORATION (US) | 2010-09-30 | — | — | WO | claimed |
| EP-2087133-A2 | IMPROVED HYBRIDISATION OF NUCLEIC ACIDS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2009-08-12 | — | — | EP | claimed |
| CN-101341260-A | Multi-component nucleases and methods of use thereof | JOHNSON & JOHNSON RES PTY LTD (AU) | 2009-01-07 | — | — | CN | claimed |
| WO-2008061311-A2 | IMPROVED HYBRIDISATION OF NUCLEIC ACIDS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2008-05-29 | — | — | WO | claimed |
| EP-0948256-A4 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | UNIV WASHINGTON (US) | 2007-10-24 | — | — | EP | claimed |
| US-6887707-B2 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-05-03 | — | — | US | claimed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | claimed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | SLC28A1 891/4885SLC28A2 952/4885SLC29A1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.